Follow
Martin Schwill
Martin Schwill
UZH/ETH
Verified email at bioc.uzh.ch
Title
Cited by
Cited by
Year
Designed ankyrin repeat proteins (DARPins): from research to therapy
R Tamaskovic, M Simon, N Stefan, M Schwill, A Plückthun
Methods in enzymology 503, 101-134, 2012
1592012
Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2
C Jost, J Schilling, R Tamaskovic, M Schwill, A Honegger, A Plückthun
Structure 21 (11), 1979-1991, 2013
1512013
Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS–p110 crosstalk
R Tamaskovic, M Schwill, G Nagy-Davidescu, C Jost, DC Schaefer, ...
Nature Communications 7 (1), 11672, 2016
462016
Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer
M Schwill, R Tamaskovic, AS Gajadhar, F Kast, FM White, A Plückthun
Science signaling 12 (565), eaau2875, 2019
352019
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
F Kast, M Schwill, JC Stüber, S Pfundstein, G Nagy-Davidescu, ...
Nature Communications 12 (1), 3790, 2021
312021
Bispecific HER2 ligands for cancer therapy
R Tamaskovic, M Schwill, A Pluckthun, C Jost
US Patent 10,093,740, 2018
28*2018
Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization
JC Stüber, CP Richter, JS Bellón, M Schwill, I König, B Schuler, J Piehler, ...
Communications Biology 4 (1), 762, 2021
132021
High-throughput generation of bispecific binding proteins by Sortase A–mediated coupling for direct functional screening in Cell Culture
F Andres, M Schwill, YL Boersma, A Plückthun
Molecular cancer therapeutics 19 (4), 1080-1088, 2020
112020
Bispecific HER2 ligands for cancer therapy
R Tamaskovic, M Schwill, A Pluckthun, C Jost
US Patent 10,093,740, 2018
62018
Bispecific HER2 Ligands for Cancer Therapy
A Plückthun, F Kast, M Schwill, A Honegger, R Tamaskovic, C Jost
US Patent App. 17/577,055, 2022
2022
Her2-binding tetrameric polypeptides
F Kast, M Schwill, A Honegger, J Stüber, R Tamaskovic, A Plückthun
US Patent App. 17/282,781, 2021
2021
Bispecific HER2 Ligands for Cancer Therapy
A Plückthun, F Kast, M Schwill, A Honegger, R Tamaskovic, C Jost
US Patent App. 16/153,857, 2019
2019
Biparatopic DARPins for Anti-ErbB2 Therapy: Intermolecular Trapping of ErbB2/HER2 Receptor Induces pan-ErbB Inhibition and Overcomes the Signaling Robustness in ErbB2-Dependent …
M Schwill
University of Zurich, 2017
2017
Targeting ErbB2 Receptor and Analysis of ErbB2-driven Oncogenic Networks
M Schwill
Universität Zürich, 2017
2017
Bispecific her2 ligands for cancer therapy
R Tamaskovic, M Schwill, A Plückthun, C Jost
2014
The system can't perform the operation now. Try again later.
Articles 1–15